European study green-lights Israeli test for recurrence of bladder cancer

Nucleix’s urine analysis studies cells for DNA changes that could signal a repeat of the EU’s fifth-most frequently diagnosed cancer. Israeli startup Nucleix Ltd., a cancer detection screening company, has developed a urine test that it says can detect with high levels of accuracy the recurrence of bladder cancer in patients.

Subscribe to one of our social media channels

close

Subscription Confirmation Required

Go to your email inbox

Go to your email inbox

Go to the inbox of the email
address you just used to sign up.

Open the confirmation email

Open the confirmation email

Find the email sent by us. It has the subject line
“Nucleix: Please Confirm Subscription” and I
sent from “info@nucleix.com”.

Click the confirmation link

Click the confirmation link

Click on the link inside the <br>email and you’re good to go.

GOT IT !